Social media

Patient leadership is a catalyst for innovation in ultra rare diseases. Hear directly from leaders who are challenging regulatory norms, driving first in human treatments and bringing hope and treatments to families fast...

Rare Disease Day takes place on 28 February. ICON is committed to raising awareness for the 300 million people impacted globally. Over the past 5 years, ICON has participated in 810+ rare disease clinical studies, enro...

Heading to ADPD 2026? Visit ICON at booth \#29 to discuss how our early development and neuroscience teams support more informed decision making in neurodegenerative research. With in house early phase capabilities and...

Heading to ADPD 2026? Visit ICON at booth #29 to discuss how our early development and neuroscience teams support more informed decision making in neurodegenerative research. With in house early phase capabilities and ...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in Select Science explores the evolving NIT landscape, emerging regulat...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

In recognition of Rare Disease Day, join ICON’s Centre for Rare Diseases for an inspiring panel at our upcoming webinar on 3 March at 11 am EST. Hear directly from parent and patient leaders whose advocacy is driving f...

2025 signalled a reset for global biotech, with capital discipline, shifting partnership models and sharper execution shaping the year. Asia’s expanding R&D footprint further underlined the sector’s geographic diversific...

2025 signalled a reset for global biotech, with capital discipline, shifting partnership models and sharper execution shaping the year. Asia’s expanding R&D footprint further underlined the sector’s geographic diversific...

The EU Joint Clinical Assessment is already influencing how oncology therapies are developed and assessed across Europe. In this article, Dr. Liz O’Brien of ICON explains how #JCA is driving earlier evidence generation, ...